• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Maternal Age Modify the Risk Associated with Short Interpregnancy Interval?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Schummers et al. ( JAMA Internal Medicine, 2018) sought to determine whether maternal age modifies the association between short interpregnancy (delivery to conception) interval and adverse pregnancy outcomes

METHODS:

  • Population-based cohort study
    • ≥2 singleton pregnancies
  • Risks of each outcome for 3- to 24-month interpregnancy intervals were estimated, according to maternal age at index birth
    • 20-34
    • ≥35 years
  • Main outcomes
    • Maternal mortality or severe morbidity: Mechanical ventilation, blood transfusion >3 U, intensive care unit admission, organ failure, death)
    • SGA: <10th percentile BW for gestational age and sex
    • Fetal and infant composite outcome: Stillbirth, infant death, <3rd BW percentile for gestational age and sex, delivery <28 weeks
    • Spontaneous and indicated preterm delivery

RESULTS:

    • 148,544 pregnancies subsequent to a live birth
    • Risk curves were U- or L-shaped
      • Nadirs for the various outcomes were approximately 18 months
      • Low risks were seen for most outcomes between 12- to 24-month intervals
    • Increased 6-month vs 18-month interpregnancy intervals for women aged 35 years or older
      • 0.62% at 6 months vs 0.26% at 18 months
      • Adjusted risk ratio (RR) 2.39 (95% CI, 2.03-2.80)
  • No increase in 6-month vs 18-month interpregnancy intervals for women aged 20 to 34 years
    • 0.23% at 6 months vs 0.25% at 18 months
    • aRR 0.92 (95% CI, 0.83-1.02)
  • Risk ratio for adverse fetal and infant outcomes comparing 6 vs 18 months were greater for women aged 20 to 34 years than women ≥35 years
    • 20 to 34 years: 2.0% at 6 months vs 1.4% at 18 months (aRR 1.42; 95% CI, 1.36-1.47)
    • ≥35 years: 2.1% at 6 months vs 1.8% at 18 months (aRR 1.15; 95% CI, 1.01-1.31)
  • Risk ratio for spontaneous preterm delivery comparing 6 months to 18 months was greater for women 20 to 34 years
    • 20 to 34 years: 5.3% at 6 months vs 3.2% at 18 months (aRR 1.65; 95% CI, 1.62-1.68)
    • ≥35 years: 5.0% at 6 months vs 3.6% at 18 months (aRR 1.40; 95% CI, 1.31-1.49)

CONCLUSION:

  • Short interpregnancy intervals that are less than <12 months are associated with increased risk for adverse pregnancy outcomes for all women across all ages
  • These risks persist after stratifying based on maternal age
  • The authors also state

Our findings indicate a shorter optimal interval than previously thought (12-24 months) for women of all ages. This finding may be reassuring particularly for older women who must weigh the competing risks of increasing maternal age with longer interpregnancy intervals

Learn More – Primary Sources:

Association of Short Interpregnancy Interval With Pregnancy Outcomes According to Maternal Age

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Interpregnancy Interval and Adverse Perinatal Outcomes 
Benefit or Risk to Delaying Pregnancy after Miscarriage?
Maternal Age: What is the Impact on Stillbirth and Other Adverse Pregnancy Outcomes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site